

mutations in the SHR that do not impact on the molecular weight of the native protein, but may affect its post-translational modification (PTM). This notion is supported by additional data, which suggest an alteration in O-linked N-acetylglucosamination.

Conclusion: Our results emphasize the role of the SHR Cd36 gene defect as the factor underlying its cardiac restricted LCFA utilization. The functional impact of this gene defect includes alterations in CD36 protein level and susceptibility to PTM.

255

In vivo detection of non-occlusive thrombi in drug-eluting stents by scintigraphy and radio-labelled annexin V in a rabbit model

Francis Blackwell (1), Anne Meddahi-Pellé (2), Graciella Pavon-Djavid (3), François Rouzet (1), Liliane Louedec (2), Laure Sarda (1), Alain Meulemans (1), Didier Letourneur (4), Christophe Hélayr (5), Laurent Feldman (6), Jean-Baptiste Michel (2), Dominique Le Guludec (1), Fabien Hyafil (1)

(1) CHU Bichat, Université Paris 7 Denis-Diderot, Service de Médecine Nucléaire et INSERM 698, Paris, France - (2) INSERM 698, Paris, France - (3) Université Paris 13, Institut Galilée, Villetaneuse, France - (4) INSERM 698 et Université Paris 13, Paris, France - (5) Université Pierre et Marie Curie, UMR7574 Chimie de la Matière Condensée de Paris, Paris, France - (6) CHU Bichat, Service de Cardiologie, Paris, France

Introduction: Thrombi in contact with non re-endothelialized stent struts associated with drug-eluting stent (DES) thrombosis. Hence, detection of thrombi in DES could help to evaluate the risk of DES thrombosis. Annexin V radio-labelled with 99mTechnetium (99mTc) is a radio-tracer with a high affinity for activated platelets.

Objectives: Our objectives were: 1) to develop an animal model of non-occlusive thrombosis of stents, 2) to evaluate the ability of annexin V 99mTc for the detection of in-stent thrombi using scintigraphy.

Methods: Right carotid arteries of NZW rabbits (n = 14) fed a high cholesterol diet were implanted with overlapping DES (n = 7) or bare-metal stents (BMS; n = 7). Four weeks after stent implantation, rabbits underwent a first scintigraphy 3 hours after injection of 200 MBq of radio-labelled annexin V 99mTc. At the end of the first scintigraphy, a suture was placed surgically proximal to the stented carotid arteries in order to induce a thrombus-prone flow limiting stenosis. Four days later, a second scintigraphy was performed. After the second scintigraphy, stents were excised, imaged ex vivo and then fixed for histological examination and scanning electron microscopy (SEM).

Results: Activities measured in vivo in the stented carotid arteries after injection of annexin V 99mTc were higher on the second scintigraphy after creation of a surgical stenosis as compared to the first scintigraphy (0.24 vs. 0.15 counts/pixel/ MBq, respectively; p<0.05). On the second scintigraphy, activities were higher in DES vs. BMS (0.26 vs. 0.19 counts/pixel/ MBq, respectively; p<0.005). High activities measured in stents in vivo were associated with the detection of thrombi on corresponding histological sections and SEM.

Conclusions: In this work, we developed a rabbit model of non-occlusive thrombosis of stents in carotid arteries. In this model, in-stent thrombi could be detected using annexin V 99mTc scintigraphy.

256

The metabolic effects of glutamine in the heart beyond anaplerosis : role of the hexosamine biosynthetic pathway

Benjamin Lauzier (1), Bertrand Bouchard (1), Fanny Vaillant (1), François Labarthe (2), Caroline Daneault (1), Isabelle Robillard-Frayne (1), Julie Thompson-Legault (1), Roselle Gélinas (1), John Chatham (3), Christine Des Rosiers (1)

(1) Institut de Cardiologie de Montréal, Laboratoire de Métabolisme Intermédiaire, Montréal, Canada - (2) CHRU de Tours, Université François Rabelais, INSERM U921, Tours, France - (3) Division of Cardiovascular Disease, Department of Medicine, Birmingham, Etats-Unis

Aim: Glutamine is the most abundant amino acid in the plasma, and has been shown to exert cardioprotective effects. However, the underlying mechanisms remained unclear, but may include an anaplerotic effect via its metabolic conversion to citric acid cycle (CAC) intermediates or activation of the hexosamine biosynthetic pathway (HBP).

Methods: To assess the potential roles of these mechanisms, we evaluated the metabolic effects of a physiologically relevant concentration of glutamine (0.5mM) in isolated working rat hearts perfused with ¹³C-labeled substrates with or without 20 M azaserine (an HBP inhibitor) and under restricted supply of carbohydrates (CHO, i.e. without pyruvate/insulin).

Results: When perfused with a mixture of CHOs, a fatty acid oleate and insulin (controls), the addition of glutamine had no effect on functional parameters except for a 17% (p<0.05) decrease in relaxation. However it resulted in an increase in the percent contribution of ¹³C-oleate to acetyl-CoA production (51%) and triglyceride formation (2.8 folds). This was accompanied by a significant reduction (p>0.05) tissue levels of the CAC intermediates (in nmol/gww): citrate: 260±10 vs. 222±6 and malate 128±5 vs. 103±3. Inhibition of HBP with azaserine restored oleate oxidation and tissue CAC levels, but not triglyceride formation. When perfused under restricted supply of CHOs, hearts displayed significantly decreased cardiac output (65%), a greater percent contribution of glucose to pyruvate formation (60%), and lower tissue citrate and malate levels (45%). Addition of glutamine restored cardiac output and glucose contribution to pyruvate formation but not tissue CAC levels.

Conclusion: Collectively, these results demonstrate the capacity of glutamine to modulate energy substrate selection and function in the perfused heart. Furthermore, the potential mechanisms underlying these effects appear to be mediated via the HBP rather than anaplerosis.

257

Prevalence of aspirin resistance in stable coronary heart diseased patients and correlation with platelet turn-over.

Thibaut Petroni (1), Sebastian Voicu (2), Bernadette Boval (3), Georges Sideris (2), Jean-Guillaume Dillinger (2), Claire Bal Dit Sollier (3), Ludovic Drouet (3), Patrick Henry (2)

(1) CHU Pitié Salpêtrière, Institut de cardiologie, Service de Réanimation Médicale, Paris, France - (2) CHU Lariboisière, Département de Cardiologie, Paris, France - (3) CHU Lariboisière, Service d'Hématologie-Hémostase, Paris, France

Background: Aspirin resistance has been widely reported but the underlying mechanisms remain unclear. Previous studies have suggested a relationship between accelerated platelet turn-over and aspirin resistance in patients with coronary artery disease. The purpose of this study was to determine whether aspirin resistance could be linked to accelerated platelet turn-over.

Methods: We performed a prospective monocentric study including 50 consecutive patients with stable coronary artery disease treated by aspirin (75 to 250 mg/day) without any other antiaggregant treatment. Aspirin resistance was characterized 24 hours after aspirin intake by light transmission aggregometry using 0.5 mg/mL arachidonic acid. Aspirin resistance was defined as >20% residual aggregation. Platelet turn-over was estimated at the same time by measurement of mean platelet volume, % of reticulated platelets, serum P-selectin, platelet P-selectin and serum thrombopoietin.

Results: Among 50 patients (70±11 y.o. mean±1.5, 76% male, 52% type 2 diabetes mellitus, 16% active smokers), 18 (36%) were identified as aspirin resistant. Table 1 shows the mean value of markers currently linked to platelet turn-over depending on the presence of aspirin resistance. Serum thrombopoietin was significantly increased in patients with aspirin resistance compared to patients with no aspirin resistance. No statistical difference was demonstrated for mean platelet volume, reticulated platelets, platelet P-selectin and serum P-selectin. Serum thrombopoietin values were not correlated with other platelet turn-over parameters. There was no significant correlation between serum thrombopoietin and inflammatory markers.

Conclusion: Serum thrombopoietin is associated with aspirin resistance, but no other parameters currently linked to platelet turn-over. Further studies are needed to determine whether serum thrombopoietin can predict aspirin resistance in a larger cohort.